Zenas BioPharma's Key Milestones And Market Context: Holding Through The BLA [Seeking Alpha]
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Seeking Alpha
ZBIO's valuation is elevated, with trailing EV/sales at 86.9x, reflecting high expectations for regulatory success and commercial transition. The Phase 3 INDIGO trial for obexelimab showed robust efficacy and safety, but market reaction was muted due to perceived lack of best-in-class differentiation. ZBIO's strong $360.5M cash position and non-dilutive debt facility support operations into late 2027, but execution risk remains high given modest current revenue. PeopleImages/iStock via Getty Images Thesis Zenas BioPharma ( ZBIO ) has a very catalyst-rich 2026 roadmap . The main investor focus would be on regulatory filings and some key clinical readouts. I see the most important near-term milestone being the planned
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma (ZBIO) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 MillionGlobeNewswire
- Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common StockGlobeNewswire
- ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]Yahoo! Finance
ZBIO
Earnings
- 3/16/26 - Miss
ZBIO
Sec Filings
- 4/2/26 - Form SCHEDULE
- 4/2/26 - Form 4
- 4/1/26 - Form 4
- ZBIO's page on the SEC website